Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer cells along with or without brain metastases: a stage 3b\/4 test

.Attribute Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ state-of-the-art breast cancer and active or even secure brain metastases revealed steady intracranial activity and also wide spread efficacy of T-DXd.

Articles You Can Be Interested In

• Nutrition
• Debt Management
• Personal Finance
• Productivity
• Science
• Self-Help
• E-commerce
• Management
• Entrepreneurship
• Credit
• Online Marketing
• Environmental Issues
• Blockchain
• Entertainment
• Data Science
• Entrepreneurship
• Health Tips
• Weddings
• Career Advice
• Manufacturing